company background image


Last Price


Market Cap







25 Jun, 2022


Company Financials +
UCB fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance5/6
Financial Health6/6

UCB Stock Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases.

UCB Competitors













Price History & Performance

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price€80.94
52 Week High€116.05
52 Week Low€74.74
1 Month Change-2.08%
3 Month Change-24.46%
1 Year Change-6.71%
3 Year Change11.00%
5 Year Change34.39%
Change since IPO1,671.43%

Recent News & Updates

Jun 06
Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

UCBBE PharmaceuticalsBE Market

Return vs Industry: UCB exceeded the Belgian Pharmaceuticals industry which returned -10.3% over the past year.

Return vs Market: UCB exceeded the Belgian Market which returned -11.3% over the past year.

Price Volatility

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement4.5%
10% most volatile stocks in BE Market8.0%
10% least volatile stocks in BE Market2.5%

Stable Share Price: UCB is not significantly more volatile than the rest of Belgian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: UCB's weekly volatility (5%) has been stable over the past year.

About the Company

19258,284Jean-Christophe Tellier

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus.

UCB Fundamentals Summary

How do UCB's earnings and revenue compare to its market cap?
UCB fundamental statistics
Market Cap€15.31b
Earnings (TTM)€1.06b
Revenue (TTM)€5.78b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UCB income statement (TTM)
Cost of Revenue€1.44b
Gross Profit€4.34b
Other Expenses€3.28b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)5.58
Gross Margin75.11%
Net Profit Margin18.26%
Debt/Equity Ratio23.7%

How did UCB perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is UCB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UCB?

Other financial metrics that can be useful for relative valuation.

UCB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.8x
Enterprise Value/EBITDA10.1x
PEG Ratio1.6x

Price to Earnings Ratio vs Peers

How does UCB's PE Ratio compare to its peers?

UCB PE Ratio vs Peers
The above table shows the PE ratio for UCB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average23.4x

Price-To-Earnings vs Peers: UCB is good value based on its Price-To-Earnings Ratio (14.5x) compared to the peer average (23.4x).

Price to Earnings Ratio vs Industry

How does UCB's PE Ratio compare vs other companies in the Pharmaceuticals Industry?

Price-To-Earnings vs Industry: UCB is good value based on its Price-To-Earnings Ratio (14.5x) compared to the European Pharmaceuticals industry average (18.6x)

Price to Earnings Ratio vs Fair Ratio

What is UCB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UCB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate UCB's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of UCB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: UCB (€80.94) is trading below our estimate of fair value (€222.33)

Significantly Below Fair Value: UCB is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: UCB is poor value based on its PEG Ratio (1.6x)

Discover undervalued companies

Future Growth

How is UCB forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: UCB's forecast earnings growth (9.1% per year) is above the savings rate (1.1%).

Earnings vs Market: UCB's earnings (9.1% per year) are forecast to grow slower than the Belgian market (16% per year).

High Growth Earnings: UCB's earnings are forecast to grow, but not significantly.

Revenue vs Market: UCB's revenue (3.5% per year) is forecast to grow faster than the Belgian market (1.9% per year).

High Growth Revenue: UCB's revenue (3.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: UCB's Return on Equity is forecast to be low in 3 years time (12.9%).

Discover growth companies

Past Performance

How has UCB performed over the past 5 years?

Past Performance Score


Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: UCB has high quality earnings.

Growing Profit Margin: UCB's current net profit margins (18.3%) are higher than last year (13.7%).

Past Earnings Growth Analysis

Earnings Trend: UCB's earnings have grown by 7.7% per year over the past 5 years.

Accelerating Growth: UCB's earnings growth over the past year (44.1%) exceeds its 5-year average (7.7% per year).

Earnings vs Industry: UCB earnings growth over the past year (44.1%) exceeded the Pharmaceuticals industry 17.9%.

Return on Equity

High ROE: UCB's Return on Equity (12.6%) is considered low.

Discover strong past performing companies

Financial Health

How is UCB's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: UCB's short term assets (€3.7B) exceed its short term liabilities (€2.8B).

Long Term Liabilities: UCB's short term assets (€3.7B) exceed its long term liabilities (€3.0B).

Debt to Equity History and Analysis

Debt Level: UCB's net debt to equity ratio (8.1%) is considered satisfactory.

Reducing Debt: UCB's debt to equity ratio has reduced from 30.4% to 23.7% over the past 5 years.

Debt Coverage: UCB's debt is well covered by operating cash flow (78%).

Interest Coverage: UCB's interest payments on its debt are well covered by EBIT (36.5x coverage).

Balance Sheet

Discover healthy companies


What is UCB current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: UCB's dividend (1.61%) isn’t notable compared to the bottom 25% of dividend payers in the Belgian market (1.95%).

High Dividend: UCB's dividend (1.61%) is low compared to the top 25% of dividend payers in the Belgian market (5.96%).

Stability and Growth of Payments

Stable Dividend: UCB's dividends per share have been stable in the past 10 years.

Growing Dividend: UCB's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (23.3%), UCB's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (23.2%), UCB's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Jean-Christophe Tellier (62 yo)





Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively and also was an Interim Chief Financial Officer since...

CEO Compensation Analysis

Compensation vs Market: Jean-Christophe's total compensation ($USD6.59M) is above average for companies of similar size in the Belgian market ($USD2.19M).

Compensation vs Earnings: Jean-Christophe's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: UCB's management team is considered experienced (4.7 years average tenure).

Board Members

Experienced Board: UCB's board of directors are considered experienced (4.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

UCB SA's employee growth, exchange listings and data sources

Key Information

  • Name: UCB SA
  • Ticker: UCB
  • Exchange: ENXTBR
  • Founded: 1925
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €15.312b
  • Shares outstanding: 189.17m
  • Website:

Number of Employees


  • UCB SA
  • Allée de la Recherche, 60
  • Brussels
  • Brussels
  • 1070
  • Belgium


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/25 00:00
End of Day Share Price2022/06/24 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.